Effetti avversi cutanei da terapie target nei pazienti immunocompromessi
The increasing use of target therapies, in the form of monoclonal antibodies and small molecule kinase inhibitors, to manage cancers or autoimmune inflammatory diseases has substantially improved the quality of life of these patients. Therefore, a new category of dermatological adverse events due to these new drurgs, is growing up, requiring specific skills by clinicians. There is an increasing need of a better knowledge of type of side effects (involving the skin, the annexes and the mucosae), of the drugs responsible for each of them in order to offer an optimal management and to optimize the care and improve the quality of life of these patients.
The project will last for one year, after which the data obtained will be extracted and analyzed.
This project is aimed to collect data about the incidence and the kind of cutaneous adverse events due to target therapies and to develop a flowchart with guidelines on better management.
This job comes from a partnership with Science Magazine and